Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Neoplasms 3Solid Tumor 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Melanoma 1Adenocarcinoma 1

Interventions

Gemcitabine 14Cisplatin 13Capecitabine 11Paclitaxel 9Oxaliplatin 9Fluorouracil 9130-nm albumin-bound paclitaxel 9pembrolizumab 7Albumin-Bound Paclitaxel 7Ramucirumab 6Leucovorin 6Carboplatin 6Bevacizumab 6Nivolumab 5Irinotecan 5Docetaxel 5Pemetrexed 4Everolimus 4Erlotinib Hydrochloride 4Cyclophosphamide 4trastuzumab deruxtecan 3Radiotherapy 3Afatinib 3zolbetuximab 2trifluridine tipiracil drug combination 2regorafenib 2pralsetinib 2cabozantinib 2Trastuzumab 2Ipilimumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Adenocarcinoma × LY3022855 × Clear all
NCT03153410 2025-01-09

Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase EARLY_PHASE1 Completed
11 enrolled 14 charts
Gastrointestinal

Adenocarcinoma, Neoplasms, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡